



FUNGUS CAN HIDE FROM

# Sporanox<sup>\*</sup>

itraconazole 100 mg

One of the notorious problems with fungal infections of the skin or the vagina is that the organism may penetrate the deeper layers of the epithelium, out of reach of topical medication. And besides, when treating fungal skin lesions locally, the infection is often already subclinically present at other sites of the body, waiting for a chance to start the trouble all over again.

Because Sporanox works orally, i.e. "from the inside out", it will destroy even the best hidden fungal cells. All the more so, because Sporanox has a strong affinity for epidermal and mucosal tissues as well as for the fungal cell wall itself where it must exert its fungicidal activity.

## SHORT AND SIMPLE ORAL THERAPY

**Standard dose in Dermatology:** 1 capsule (100 mg) once daily for 15 days  
(Sporanox will remain active in the stratum corneum for another 3-4 weeks)

**Standard dose in Gynaecology:** 2 x 2 capsules (400 mg) for 1 day only  
(Sporanox will remain active in the vaginal epithelium for another 3 to 4 days)

This product is not yet available in all countries.

**\* Trademarks:** SPORANOX, SEMPERA, TRISPORAL, SPORAL.

**Properties:** Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, fungal keratitis and oral candidosis. **Dosage and administration:** Vulvovaginal candidosis: 2 cap-

sules (200 mg) morning and evening for 1 day, Pityriasis versicolor: 2 capsules (200 mg) once daily for 7 days. - Tinea corporis, tinea cruris, tinea pedis, tinea manus: 1 capsule (100 mg) daily for 15 days; highly keratinized regions, as in plantar tinea pedis and palmar tinea manus, require 1 capsule (100 mg) daily for 30 days. - Oral candidosis: 1 capsule (100 mg) daily for 15 days. - Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole) is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanox (itraconazole) has not been associated with hepatic dysfunction, it is

advisable not to give this drug to patients with a known history of liver disease. **Nursing mothers:** It is recommended not to breast feed whilst taking Sporanox (itraconazole). **Drug interactions:** Sporanox (itraconazole) should not be given concomitantly with rifampicin.

Full prescribing information is available on request.



**JANSSEN**  
PHARMACEUTICA  
2340 Beerse, Belgium  
the drug discovery company

**In association with the British Cardiac Society**

EDITOR: **M.J. DAVIES**

**Associate Editors: Kim Fox, Peter Mills**

Is a major international journal which concentrates on providing up to date clinical information. Found worldwide in leading libraries, and read by physicians and surgeons with more general interests, as well as by cardiologists, features include concise, readable editorials, written by international experts, which tie in with original research papers published in areas vital to the development of cardiology.

- Recent Issues included a review by Professor Swales on the interplay between the beneficial properties of diuretics and  $\beta$  blockers in hypertension and the potentially adverse effect on plasma lipids. The rationale of single lung transplantation in end stage lung disease is discussed by the Newcastle group.
- The Festschrift Issue marking the editorship of Dr D Krikler included a review of the progress in the genetic basis of hypertrophic cardiomyopathy and records the gene defect in an original family from the Teare paper of 1958.

- **Future Issues report trial evidence (European Cooperative Study Group) on the effect of early Intravenous heparin on coronary patency Infarct size and bleeding complications after alteplase therapy.**
- **Future editorials include Coronary Heart Disease In South Asians, Stress Proteins and the Myocardium and the Role of Antiphospholipid Antibodies in Cardiac Disease. An important study from Tom Meade (MRC epidemiology unit Northwick Park) possibly explains the beneficial effect of exercise by showing that it reduces fibrinogen levels.**
- **As well as original articles and editorials, British Heart Journal also publishes case reports, letters and working party recommendations for clinical practice e.g. Recommendations for pacemaker prescription for symptomatic bradycardia.**

**1992 Subscription Rate: £156, USA Only: \$255**  
**Combined Subscription with *Cardiovascular Research*: £293, USA Only: \$521**

**To Order Your Subscription or Sample Copy  
Please Complete the Order Form Below:**

# BRITISH HEART JOURNAL

ISSN: 0007-0769

**PUBLICATION:** Monthly

**1992 SUBSCRIPTION RATE: £156, USA ONLY: \$255**

**COMBINED SUBSCRIPTION WITH CARDIOVASCULAR  
RESEARCH: £293. USA ONLY: \$521**

**Please tick**

- ☐ Please enter my subscription, start date \_\_\_\_\_
- ☐ Please send me a sample copy
- ☐ Please send me *Instructions to Authors*
- ☐ I enclose a cheque for \_\_\_\_\_  
(Payable to British Medical Journal)
- ☐ I wish to pay by credit card.

**American Express/Visa(Barclaycard)/Mastercard**  
(Delete as appropriate)

**BM]**

Send orders to: **BMJ Publishing Group, BMA House, Tavistock Square, London. WC1H 9JR.**  
or **BMJ Publishing Group, Box No 560B, Kennebunkport, Maine 04046 (Direct Orders Only)**

**Card Number**

[illegible]

**MasterCard users should add the numbers appearing above their name**

**Expiry date**



**Signature**

*(Your signature is essential, especially when paying by credit card)*

**Name** (Capitals)**Address**

Date \_\_\_\_\_

# Concise and comprehensive guides for all medical practitioners



## ABC OF AIDS Edited by Michael W Adler

The second edition of the ABC OF AIDS has been completely revised to give a clear picture of the present state of knowledge about the epidemic and current approaches to treatment. It also includes two new chapters, on HIV infection related to mis-use of drugs, and HIV infection in children.

"...the single best concise source on aids."

*Journal of the American Academy of Dermatology*

"... this book can be strongly recommended to those who need a concise but comprehensive account of the problems of HIV and AIDS and current understanding of its management."

*International Journal of Epidemiology*

### 2nd Edition

UK £11.95; Abroad £13.50.

BMA members £10.95 or £12.50

## AIDS AND THE LUNG

Edited by David Mitchell, Ashley Woodcock

In *AIDS and the Lung* experts review the problems, emphasising practical points and providing up to date information on this rapidly changing subject. This is an indispensable handbook for respiratory physicians, especially those with limited experience of dealing with AIDS and for everyone concerned with protective measures in bronchoscopy units and pulmonary function laboratories.

" This book is a beauty! ...it is interesting and it answered many questions on the respiratory consequences of AIDS... great value for all practitioners who deal with AIDS and the lung."

*The Medical Journal of Australia*

UK £8.95; Abroad £10.00.

BMA members £8.45 or £9.50



## ABC OF SEXUALLY TRANSMITTED DISEASES Michael W Adler

Doctors need to be aware that common clinical conditions such as rashes, vaginal discharge, and pelvic pain may have a sexual origin and in the second edition of the ABC of Sexually Transmitted Diseases Professor Michael Alder gives expert guidance on the diagnosis and management of these conditions.

"... an excellent basic book for the non-specialist, the medical student, and for nursing and paramedical staff associated with genitourinary medicine."

*Genitourinary Medicine*

"... an excellent starting point for the novice or an equally valuable reference for the experienced clinician. It is quick and easy to read..."

*Canadian Medical Association Journal*

### 2nd Edition

UK £11.95; Abroad £13.50.

BMA members £10.95 or £12.50

O  
R  
D  
E  
R  
  
F  
O  
R  
M

British Medical Journal. PO Box 295, London WC1H 9TE

Please send me the following books:

QTY	TITLE	AMOUNT
Prices include postage, by air abroad		TOTAL

NAME \_\_\_\_\_

(Print clearly)

ADDRESS \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

POSTCODE \_\_\_\_\_

Membership No \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No \_\_\_\_\_ Exp \_\_\_\_\_

Signature \_\_\_\_\_

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only)

☐ Please send me a BMJ book catalogue



# Guarding the Guardians: Research on

## EDITORIAL PEER REVIEW

Following the success of the American Medical Association's First International Congress on Peer Review in Biomedical Publication, a second such Congress is being planned for September 1993. We aim to present original research on critical issues in the publication of all clinical and scientific research.

What are such critical issues?

- The mechanisms of peer review and editorial decision making in different journals
- The relationships between authors, editors, and reviewers, and how each is educated, selected, and evaluated.
- Allocation of responsibility for published material
- Quality assurance
- Breakdowns, weaknesses, and biases

For more information on attending or presenting research, contact:

Jane Smith, BA, MSc  
Managing Editor, *BMJ*  
BMA House  
Tavistock Square  
London WC1H 9JR  
Telephone: 071-387-4499  
Facsimile: 01-383-6418



### BEGIN PLANNING YOUR RESEARCH PROTOCOLS NOW!

## Forum for the Evaluation of Anti-infective Therapy

Rome Italy  
27-29 November 1992



### ANTIBIOTICS AND THE RESPIRATORY TRACT

The first Forum for the Evaluation of Anti-infective Therapy will take place at the Sheraton Roma Hotel and Conference Center, Rome, Italy, on 27-29 November 1992. The focus of the congress will be the examination of the evaluation of criteria for the diagnosis of respiratory infections and also the choice of appropriate antibiotic treatment and the associated problems presenting to the prescribing physician.

#### Topics:

- Evaluation of criteria for the diagnosis of respiratory infection
- Evaluation of antibiotics for treatment of respiratory infections
- The severity of respiratory infections and the therapeutic response
- The influence of age on treatment of respiratory infections
- An interactive session on the treatment of selected cases

#### Prestigious international faculty

**Scientific Committee:** David Williams (UK) Tom Bergan (Norway)  
Vincent Andriole (US) Carlo Grassi (Italy)  
Claude Carbon (France) Robert Moellering (US)  
Giuliana Gialdroni Grassi (Italy)

Non-residential registration fee US\$ 360.00

Residential registration fee US\$ 800.00

Total number of participants limited to 450; some places still available

Further details and application forms from: Lindsey Whitehouse, FEAT Congress Secretariat, International Clinical Forum (ICF) Consultants Ltd, Wicker House, 3 Liverpool Gardens, Worthing, West Sussex BN11 1TF, UK. Telephone: +44 (0)903 205213. Fax: +44 (0)903 210296.

## International Medical Course

### Nursing care of people with HIV disease

2-15 May 1993, London

The purpose of this course is to provide nurses with space and an opportunity to explore the complexity of the issues involved in HIV disease. It is designed for senior nurses, nursing administrators, clinical nurse managers, managers of patient care and lecturers in schools and colleges of nursing.

The Director of Studies will be **Mr Robert J Pratt**, Vice Principal and Head of Faculty of Vocational & Professional Practice, Riverside College of Health Studies, London.


There are vacancies for 35 participants.

Course fee: £960; Accommodation charge: £595; total fee: £1,555.

The course will be held at The Riverside College of Health Studies at the Charing Cross Hospital, London. Resident participants will be accommodated in single bedrooms with private facilities at a West London hotel.

**The British Council**

Further information and application forms are available from your local British Council office or from Courses Department, The British Council, 10 Spring Gardens, London SW1A 2BN.



#### Second edition

UK £9.95; Abroad £11.00  
(BMA members £9.45 or £10.50)  
including postage, by air abroad

**ORDER YOUR COPY  
NOW**

## A portable reference for aerospace medicine

"... can be thoroughly recommended ... provide[s] enjoyment and education to all concerned with the medical aspects of conventional and unconventional flight ..."

*Aerospace*

"... easy to read and informative ... unequivocally recommended ..."

*Canadian Medical Association Journal*

"... a very readable and practical guide to Aerospace Medicine."

*Aviation, Space, and Environmental Medicine*

Available from: **BRITISH MEDICAL JOURNAL**,  
PO Box 295, London WC1H 9TE, medical booksellers  
or the **BMJ** bookshop in BMA House

Please send me \_\_\_\_\_ copy/ies of

AVIATION MEDICINE

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_ POSTCODE \_\_\_\_\_

I enclose \_\_\_\_\_ Please make cheques payable to **British Medical Journal**. Book tokens accepted

Debit my credit card (please tick box)

☐ Visa ☐ American Express ☐ Mastercard

Card No \_\_\_\_\_

Card expiry date \_\_\_\_\_

Signature \_\_\_\_\_

BMA Membership No \_\_\_\_\_

☐ Please send me a book catalogue



TRADEMARK

# Prepulsid

## Gets stomach and oesophagus back to work.

### Prepulsid. The force behind G.I. motility.

**Prescribing information** - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. **Therapeutic indications:** 1. Gastroparesis. 2. Symptoms of X-ray or endoscopy negative upper digestive discomfort. 3. Gastro-oesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. **Contra-indications:** No absolute contra-indications are known. **Warnings:** Caution should be observed in patients in whom an increase in gastro-intestinal motility could be harmful. **Precautions:** **Pregnancy:** Although, in animals, there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. **Nursing mothers:** Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. **Driving and machine-operating ability:** Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. **Interactions:** - The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs: absorption of drugs

from the stomach may be diminished, whereas absorption of drugs from the small bowel may be accelerated (e.g. benzodiazepines, anticoagulants, paracetamol, H<sub>2</sub>-blockers). - In patients receiving anticoagulants, the coagulation times may somewhat increase. It is advisable to check the coagulation time one week after the start of Prepulsid treatment to adapt the anticoagulant dose if necessary. The sedative effects of benzodiazepines and of alcohol may be accelerated. - The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonized by anticholinergic drugs. - In hepatic and renal insufficiency, it is recommended to halve the initial daily dose. Subsequently, this dose can be adapted, depending on the therapeutic effects or possible side-effects. - In the elderly, steady-state plasma levels are generally higher, due to a moderate prolongation of the elimination half-life. Therapeutic doses, however, are similar to those used in younger patients. - In the case of drugs that require individual titration, it may be useful to monitor plasma levels of such drugs when Prepulsid is associated. **Adverse reactions:** In line with the pharmacological activity of Prepulsid, transient abdominal cramping, borborygmi and diarrhoea may occur. Mild and transient headache or lightheadedness have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. There are isolated reports of CNS effects, i.e. convulsive seizures and

extrapyramidal effects. **Dosage:** - Adults: according to the severity of the condition, 15 to 40 mg daily, to be given in 2 to 4 intakes, to be taken as tablets or as oral suspension (the full plastic 5-ml spoon contains 5 mg). As a rule the following doses have proven adequate: • less severe conditions: 5 mg t.i.d. (dose can be doubled); • severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. to 10 mg q.i.d. (before the 3 main meals and before retiring). - Infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension, intakes are indicated on the dosing pipet as a function of body weight.

Full prescribing information available on request.

**Note:** Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.

 **JANSSEN**  
PHARMACEUTICA  
B-2340 Beerse, Belgium